Emerging data suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to represent a notable advancement for obesity loss . Early clinical tests have shown impressive losses in body mass , potentially outperforming other obesity therapies . Despite this, more evaluation is required to